MAP2K5

Across TCGA pan-cancer cohorts, MAP2K5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAP2K5 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MAP2K5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MAP2K5 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LSCC, LUAD, and HNSC are the cancer types where MAP2K5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.770	0.923	.010	5	view →
LUAD	OS	Median	II,III,IV	0.495	0.799	.021	3	view →
HNSC	DFS	Tertile	III,IV	1.000	0.921	.037	1	view →
CCRCC	OS	Quartile	All	0.913	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAP2K5–LSCC (OS)

Open the LSCC breakdown →